Publications by authors named "N Lintzeris"
Aims: This study tested the efficacy and safety of a 12-week course of lisdexamfetamine in reducing methamphetamine use, an outcome which is associated with improvements in health and wellbeing, in people dependent on methamphetamine.
Design, Setting And Participants: This study was a randomised double-blind placebo-controlled trial conducted in six specialist outpatient clinics in Adelaide, Melbourne, Newcastle and Sydney, Australia (2018-2021). Participants were164 adults with methamphetamine dependence, reporting at least 14 use days out of the previous 28 days (62% male, 38% female, < 1% other; mean age 39 years).
Aims: To compare a low-dosing protocol to standard practice for methadone-buprenorphine transfers.
Methods: We undertook a nonrandomized open-label clinical trial across 8 sites from NSW, Australia. Participants prescribed methadone wishing to transfer to buprenorphine could either choose or be randomized to a low-dose transfer or standard care transfer as per NSW health guidelines.
Article Synopsis
- - Women in alcohol and drug services face higher rates of unintended pregnancies and lower contraception access; this study investigates contraceptive initiation after offering services in metropolitan and regional areas.
- - With 91% of participants not planning to get pregnant within a year at baseline, only 21% were using effective contraception; following education and support, 28% initiated highly reliable methods, especially in regional areas (51% compared to 2% in metropolitan areas).
- - While 44% of women were using effective contraception a year later, and 15% reported pregnancies, the study suggests improved pathways for contraception can help, though there are significant site differences in outcomes that need further exploration.
Article Synopsis
- The study focuses on the costs associated with providing medication-assisted treatment for opioid dependence using extended-release buprenorphine (BUP-XR) through a detailed bottom-up cost analysis.
- Conducted in Australia, the research involved 100 participants receiving monthly BUP-XR injections, revealing an average annual treatment cost of $6,656 per client, with medication costs accounting for 95% of the monthly expense.
- The findings suggest that investing in BUP-XR treatment could optimize health system resources, making this cost data valuable for evaluating its effectiveness compared to other opioid treatments.
Introduction: Supervised injectable opioid treatment (SIOT) is an evidence-based intervention targeting opioid-dependent people for whom existing treatments have been ineffective. This project will primarily assess the feasibility and the acceptability of time-limited SIOT using injectable hydromorphone delivered in an existing Australian public opioid treatment programme, with secondary outcomes of safety, cost, changes in drug use and other health outcomes. If feasible, the goal is to scale up the intervention to be more widely available in Australia.
View Article and Find Full Text PDF